VP-102 Drug Market

"VP-102 Market Size, Forecast, and Emerging Insight – 2032” report offers an in-depth analysis of both market and emerging insights regarding VP-102 for the treatment of Molluscum contagiosum, Genital Warts, and Common Warts in the seven major markets. A detailed picture of the VP-102 in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the VP-102. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VP-102 market forecast analysis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies.

VP-102 Drug Summary

VP-102 is a proprietary drug-device combination developed by Verrica Pharmaceuticals as topical therapy, containing (0.7% w/v) of cantharidin solution designed to treat MC, common warts, and external genital warts. The patented drug-device combination is available in the single-use precision applicator for ease of administration. It is a GMP-controlled formulation of cantharidin with more than 99% pure API and a pharmaceutical batch process defined with respect to safety, purity, and stability. The active ingredient, cantharidin, is a naturally occurring vesicant that causes the degradation of desmosomal plaques, which helps treat topical dermatological conditions. Cantharidin is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A) that have keratolytic features inducing acantholysis. 

VP-102 has the potential to be a first-in-class treatment. Verrica Pharmaceuticals plans to re-submit an NDA for VP-102 to the US FDA for the treatment of treat MC in the first quarter of 2023.

Scope of the VP-102 Drug Market Report

The report provides insights into:
• A comprehensive product overview including the VP-102 description, mechanism of action, dosage and administration, research and development activities in Molluscum contagiosum, Genital Warts, and Common Warts.
• Elaborated details on VP-102 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VP-102 research and development activities in Molluscum contagiosum, Genital Warts, and Common Warts across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VP-102.
• The report contains forecasted sales of VP-102 for Molluscum contagiosum, Genital Warts, and Common Warts till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Molluscum contagiosum, Genital Warts, and Common Warts.
• The report also features the SWOT analysis with analyst views for VP-102 in Molluscum contagiosum, Genital Warts, and Common Warts.

VP-102 Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities' websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

VP-102 Analytical Perspective by DelveInsight

• In-depth VP-102 Market Assessment

This report provides a detailed market assessment of VP-102 for Molluscum contagiosum, Genital Warts, and Common Warts in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data of VP-102.

• VP-102 Clinical Assessment
The report provides the clinical trials information of VP-102 for Molluscum contagiosum, Genital Warts, and Common Warts covering trial interventions, trial conditions, trial status, start and completion dates.

VP-102 Drug Market Report Highlights  

• In the coming years, the market scenario for Molluscum contagiosum, Genital Warts, and Common Warts is set to change due to the extensive research and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VP-102 dominance.
• Other emerging products for Molluscum contagiosum, Genital Warts, and Common Warts are expected to give tough market competition to VP-102, and the launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of VP-102 in Molluscum contagiosum, Genital Warts, and Common Warts.
• Our in-depth analysis of the forecasted sales data of VP-102 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of VP-102 in Molluscum contagiosum, Genital Warts, and Common Warts. 

Key Questions

• What is the product type, route of administration, and mechanism of action of VP-102?
• What is the clinical trial status of the study related to VP-102 in Molluscum contagiosum, Genital Warts, and Common Warts, and the study completion date?
• What are the key collaborations, mergers, acquisitions, licensing, and other activities related to the VP-102 development?
• What are the key designations that have been granted to VP-102 for Molluscum contagiosum, Genital Warts, and Common Warts?
• What is the forecasted market scenario of VP-102 for Molluscum contagiosum, Genital Warts, and Common Warts?
• What are the forecasted sales of VP-102 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  
• What are the other emerging products available, and how are these giving competition to VP-102 for Molluscum contagiosum, Genital Warts, and Common Warts?
• Which are the late-stage emerging therapies under development for the treatment of Molluscum contagiosum, Genital Warts, and Common Warts?